Directorio de personas
Cristina Gonzalez Mingot

Cristina Gonzalez Mingot

973 70 52 00
cgonzalezm.lleida.ics(ELIMINAR)@gencat.cat

ResearcherID: http://www.researcherid.com/rid/OFN-4802-2025

Grupos

Publicaciones

  • Torres, P; Pradas, I; Fernàndez-Bernal, A; Povedano, M; Dominguez, R; Jové, M; Gonzalez-Mingot, C; Ayala, V; Ferrer, I; Pamplona, R; Portero-Otin, M

    Exploring platelet metabolomics and fatty acid profiles for ALS prognosis and diagnosis

    SCIENTIFIC REPORTS 15 -. .

    [doi:10.1038/s41598-025-16220-0]

  • Sancho-Saldaña, A; Gil-Sánchez, A; Quirant-Sánchez, B; Boigues, M; Canudes, M; Peralta, S; Solana, MJ; González-Mingot, C; Quibus, L; Martínez-Cáceres, E; Torres, P; Hervás, JV; Moreno-Magallon, J; Brieva, L

    Profile of Cytokines Associated with SARS-CoV2 Seropositivity in Multiple Sclerosis Patients and Its Persistence over Six Months

    Journal of Clinical Medicine 14 -. .

    [doi:10.3390/jcm14113736]

  • Santacreu-Vilaseca, M; Moreno-Magallon, J; Juanes-Casado, A; Gil-Sánchez, A; González-Mingot, C; Torres, P; Brieva, L

    Novel Cell Models to Study Myelin and Microglia Interactions

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 26 -. .

    [doi:10.3390/ijms26052179]

  • González-Mingot C.; Gil-Sánchez A.; Begué-Gómez R.; López-Ortega R.; Luis B.R.

    Ischemic encephalopathic debut of CADASIL, a case report: It is better to be safe than sorry

    NEUROLOGIA 39 712-715. .

    [doi:10.1016/j.nrl.2023.02.002]

  • Gil-Sánchez A.; Gonzalo H.; Canudes M.; Nogueras L.; González-Mingot C.; Valcheva P.; Torres P.; Serrano J.C.; Peralta S.; Solana M.J.; Brieva L.

    Can Glatiramer Acetate Prevent Cognitive Impairment by Modulating Oxidative Stress in Patients with Multiple Sclerosis?

    PHARMACEUTICALS 17 -. .

    [doi:10.3390/ph17040459]

  • Gil-Sanchez, A; Canudes, M; Valcheva, P; Nogueras, L; González-Mingot, C; Hervás, JV; Peralta, S; Solana, M; Brieva, L

    Effects of Vortioxetine on Cognition and Fatigue in Patients with Multiple Sclerosis and Depression: A Case Series Study

    CNS & Neurological Disorders-Drug Targets 23 395-401. .

    [doi:10.2174/1871527322666230321093133]

  • Gil-Perotin, S; Reddam, S; González-Mingot, C; Gil-Sánchez, A; González-Suarez, I; Peralta, S; Escrivá, P; Barea-Moya, L; Sánchez-Sánchez, B

    Reliability, validity and distribution of the Spanish female sexual function index in women with relapsing multiple sclerosis

    BMC WOMENS HEALTH 23 -. .

    [doi:10.1186/s12905-023-02811-4]

  • Sancho--Saldaña, A; Gil-Sánchez, A; González-Mingot, C; Peralta, S; Solana, MJ; Torres, P; Juanes, A; Quibus, L; Ruiz, E; Sanpedro, E; Quirant-Sánchez, B; Martínez-Cáceres, E; Tello, CR; Presas-Rodríguez, S; Rubio, SG; Baron, BP; Ramio-Torrenta, L; Sotoca, J; González-Suarez, I; Eichau, S; Prieto-Gonzalez, JM; Quilez, MRB; Sabin-Muñoz, J; Sánchez-López, AJ; Calatayud, GL; Calles, C; Sempere, AP; Garces, M; Carmona, O; Moral, E; Hervas, JV; Blanco, Y; Sola-Valls, N; Lara, NT; Forero, L; Brieva, L

    Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study

    Journal of Clinical Medicine 12 -. .

    [doi:10.3390/jcm12237243]

  • Mingot, CG; Lasaosa, SS; Campas, LC; Canaval, LC; Sánchez, AG; Ruiz, LB; Alonso, MCM; Moncusi, SP; Marsal, JV; Carner, SC; García, FP

    Prophylactic treatment can modify vascular risk biomarkers in high-frequency episodic and chronic migraine patients: a pilot study

    SCIENTIFIC REPORTS 13 19416-19416. .

    [doi:10.1038/s41598-023-44522-8]

  • Vicente-Pascual, M; Quilez, A; Gil, MP; Gonzalez-Mingot, C; Vazquez-Justes, D; Mauri-Capdevila, G; Sanahuja, J; Garcia-Vazquez, C; Purroy, F

    The influence of organisational management on door-to-needle times for fibrinolytic treatment

    NEUROLOGIA 38 313-318. .

    [doi:10.1016/j.nrl.2020.10.014]

  • González-Mingot, C; Miana-Mena, FJ; Iñarrea, PJ; Iñiguez, C; Capablo, JL; Osta, R; Gil-Sánchez, A; Brieva, L; Larrodé, P

    Mitochondrial Aconitase Enzymatic Activity: A Potential Long-Term Survival Biomarker in the Blood of ALS Patients

    Journal of Clinical Medicine 12 -. .

    [doi:10.3390/jcm12103560]

  • Torres P; Sancho-Saldaña A; Gil Sánchez A; Peralta S; Solana MJ; Bakkioui S; González-Mingot C; Quibus L; Ruiz-Fernández E; San Pedro-Murillo E; Brieva L

    A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.

    JOURNAL OF NEUROLOGY 270 1-12. .

    [doi:10.1007/s00415-023-11575-8]

Proyectos

  • Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS Patients
  • Humanised mouse models to study ATG4B cryptic exon involvement in ALS pathogenesis and its potential as disease biomarker (Hum4ALS)
  • Desregulacion de TDP-43,eje clave en la ELA: Caracterización de firmas lipidómicas, transcriptómicas y autofágicas en muestras específicas de pacientes para biomarcadores y reposicionamiento
  • The Prognostic Value of Cholesterol Esters in the Progression of Multiple Sclerosis” (PROCOLEM)
  • Metabolismo lipidico intracelular, procesamiento de ARNm y estrés celular en la encrucijada de la fisiopatología de la esclerosis lateral amiotrófica
  • BIOMARCADORES DE ESTRES OXIDATIVO Y DISFUNCION ENDOTELIAL EN MIGRAÑA
  • PREDICTUS-USE OF SYSTEM BIOLOGY TO PREDICT AND DIAGNOSE TRANSITORY ISCHEMIA AND ISCHEMIC TOLERANCE